Zacks Research Has Bearish Forecast for BDX FY2027 Earnings

Becton, Dickinson and Company (NYSE:BDX) – Equities research analysts at Zacks Research decreased their FY2027 earnings per share estimates for shares of Becton, Dickinson and Company in a note issued to investors on Monday, December 16th. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings of $16.68 per share for the year, down from their previous estimate of $16.75. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the company posted $3.42 earnings per share. The firm’s revenue was up 6.9% on a year-over-year basis.

Several other analysts have also commented on the company. Evercore ISI increased their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus target price of $283.50.

Becton, Dickinson and Company Trading Down 0.7 %

NYSE:BDX opened at $224.09 on Wednesday. The stock has a market capitalization of $64.79 billion, a price-to-earnings ratio of 37.73, a PEG ratio of 1.64 and a beta of 0.41. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $249.89. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The firm has a 50 day moving average of $230.29 and a 200 day moving average of $233.34.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be issued a $1.04 dividend. The ex-dividend date is Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.86%. Becton, Dickinson and Company’s dividend payout ratio is currently 70.03%.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 638 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the transaction, the executive vice president now owns 14,217 shares of the company’s stock, valued at $3,113,949.51. This trade represents a 4.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Becton, Dickinson and Company

Institutional investors have recently modified their holdings of the stock. Livelsberger Financial Advisory acquired a new stake in Becton, Dickinson and Company during the third quarter worth about $26,000. Ashton Thomas Securities LLC acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $33,000. Tompkins Financial Corp increased its holdings in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares in the last quarter. Sound Income Strategies LLC lifted its stake in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the period. Finally, Abound Wealth Management boosted its holdings in Becton, Dickinson and Company by 96.0% during the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 96 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.